These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23629471)

  • 1. Urological cancer: second-line option for metastatic RCC.
    Marchesi V
    Nat Rev Clin Oncol; 2013 Jun; 10(6):305. PubMed ID: 23629471
    [No Abstract]   [Full Text] [Related]  

  • 2. Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.
    Payton S
    Nat Rev Urol; 2013 Jun; 10(6):308. PubMed ID: 23649292
    [No Abstract]   [Full Text] [Related]  

  • 3. New options for second-line therapy of advanced renal cancer.
    Bex A
    Lancet Oncol; 2013 May; 14(6):450-1. PubMed ID: 23598169
    [No Abstract]   [Full Text] [Related]  

  • 4. Kidney cancer: Axitinib destined for second place?
    Payton S
    Nat Rev Urol; 2013 Dec; 10(12):678. PubMed ID: 24217676
    [No Abstract]   [Full Text] [Related]  

  • 5. Axitinib in advanced renal-cell carcinoma.
    Yousaf N; Larkin J
    Lancet Oncol; 2013 Dec; 14(13):1245-6. PubMed ID: 24206641
    [No Abstract]   [Full Text] [Related]  

  • 6. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Qin S; Zhang S
    Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
    [No Abstract]   [Full Text] [Related]  

  • 7. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tilting the AXIS towards therapeutic limits in renal cancer.
    Bex A; Haanen J
    Lancet; 2011 Dec; 378(9807):1898-900. PubMed ID: 22056245
    [No Abstract]   [Full Text] [Related]  

  • 10. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
    Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-line dovitinib in metastatic renal cell carcinoma.
    Schmidinger M
    Lancet Oncol; 2014 Mar; 15(3):245-6. PubMed ID: 24556039
    [No Abstract]   [Full Text] [Related]  

  • 13. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?
    Iacovelli R; Verzoni E; De Braud FM; Procopio G
    Cancer Biol Ther; 2014 May; 15(5):486-8. PubMed ID: 24556857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
    Cella D; Escudier B; Rini B; Chen C; Bhattacharyya H; Tarazi J; Rosbrook B; Kim S; Motzer R
    Br J Cancer; 2013 Apr; 108(8):1571-8. PubMed ID: 23579211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 18. Kidney cancer: targeting FGF for third-line treatment of mRCC.
    Payton S
    Nat Rev Urol; 2014 Apr; 11(4):186. PubMed ID: 24595120
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.